Table 2.
Influence of miR-654-5p expression and clinical risk factors on overall survival in breast cancer patients
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
|
|
||||
| Factors | HR (95% CI) | P value | HR (95% CI) | P value |
| Age (≥62/<62) | 1.47 (0.84-2.56) | 0.180 | ||
| Family history (Present/Absent) | 1.38 (0.55-3.48) | 0.495 | ||
| Tumor grade (III/I-II) | 1.91 (1.05-3.46) | 0.033 | 1.72 (0.95-3.13) | 0.073 |
| TNM stage (III-IV/I-II) | 2.36 (1.35-4.14) | 0.003 | 2.25 (1.28-3.96) | 0.005 |
| Lymph node metastasis (Present/Absent) | 2.05 (1.15-3.66) | 0.015 | 0.82 (0.27-2.46) | 0.717 |
| ER status (Positive/Negative) | 0.70 (0.40-1.23) | 0.218 | ||
| PR status (Positive/Negative) | 0.76 (0.34-1.70) | 0.506 | ||
| Her2/Neu status (Positive/Negative) | 0.79 (0.44-1.41) | 0.422 | ||
| miR-654-5p (Low/High) | 4.86 (2.47-9.56) | <0.001 | 4.74 (2.41-9.32) | <0.001 |
ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor type 2 also referred to as Her2/Neu. HR, hazard ratio; CI, confidence interval.